Literature DB >> 1684082

Activation of neurohumoral systems following acute myocardial infarction.

J L Rouleau1, L A Moyé, J de Champlain, M Klein, D Bichet, M Packer, G Dagenais, B Sussex, J M Arnold, F Sestier.   

Abstract

Previous studies have indicated that patients with an acute myocardial infarction have marked activation of all neurohumoral systems on admission to the hospital. This activation begins to subside within the first 72 hours so that by 7-10 days, all plasma neurohormones have returned to normal. The only documented exceptions were found to occur in patients with left ventricular dysfunction and overt heart failure, where both plasma renin activity and atrial natriuretic peptide were increased, and in patients with left ventricular dysfunction but no overt heart failure, where only atrial natriuretic peptide was increased. Although these studies suggest that neurohumoral activation rarely occurs at the time of hospital discharge, they were small and may have missed an important subgroup of patients with persistent neurohumoral activation. In the Survival and Ventricular Enlargement (SAVE) study, 522 patients had plasma neurohumoral levels measured at a mean of 12 days postinfarction. All SAVE patients had left ventricular dysfunction (left ventricular ejection fraction less than or equal to 40%), but no overt heart failure. In this group of patients, all neurohumoral levels (plasma renin activity, norepinephrine, arginine vasopressin, and atrial natriuretic peptide) were found to be increased compared with age-matched control subjects. These results indicate that, in fact, a subgroup of patients without overt heart failure has persistent neurohumoral activation at the time of hospital discharge postinfarction, and that this activation involves several neurohumoral systems. Since patients with persistent neurohumoral activation postinfarction are likely those most at risk of developing complications and the ones most likely to benefit from pharmacologic interventions blunting the effects of neurohumoral activation, measurement of predischarge neurohumoral levels may be useful.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684082     DOI: 10.1016/0002-9149(91)90264-l

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Neurohormonal activation in heart failure with reduced ejection fraction.

Authors:  Justin Hartupee; Douglas L Mann
Journal:  Nat Rev Cardiol       Date:  2016-10-06       Impact factor: 32.419

Review 2.  Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

Authors:  Christian Werner; Janine Pöss; Michael Böhm
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

3.  Clinical factors associated with arrhythmia and short-term prognosis following mitral valve repair: a retrospective cohort study.

Authors:  Yuxiang Zhu; Wenbin Jing; Pengfei Lv; Yubao Zhu; Zhigang Liu
Journal:  Cardiovasc Diagn Ther       Date:  2022-02

4.  Lipid management: considerations in acute coronary syndrome.

Authors:  Venkateshwar R Polsani; Salim S Virani; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2009-03       Impact factor: 5.113

5.  Lipid management: considerations in acute coronary syndrome.

Authors:  Venkateshwar R Polsani; Salim S Virani; Vijay Nambi
Journal:  Curr Cardiol Rep       Date:  2008-07       Impact factor: 2.931

Review 6.  Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: evidence from clinical trials.

Authors:  George V Moukarbel; Scott D Solomon
Journal:  Curr Heart Fail Rep       Date:  2008-12

Review 7.  ACE inhibitors versus diuretics: when to choose which drug?

Authors:  N Sharpe
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

Review 8.  Hospitalization and cognitive decline: Can the nature of the relationship be deciphered?

Authors:  Sarah B Mathews; Steven E Arnold; C Neill Epperson
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.